Influence of the N terminus on the biophysical properties and pharmacology of TREK1 potassium channels

Molecular Pharmacology

Volumn 85, Issue 5, 2014, Pages 671-681

  Veale, Emma L ^a   Al Moubarak, Ehab ^a   Bajaria, Naina ^a   Omoto, Kiyoyuki ^b   Cao, Lishuang ^b   Tucker, Stephen J ^c   Stevens, Edward B ^b   Mathie, Alistair ^a  

^a MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BL 1249; DICLOFENAC; FENAMIC ACID DERIVATIVE; FLUFENAMIC ACID; MEFENAMIC ACID; NIFLUMIC ACID; POTASSIUM CHANNEL; POTASSIUM CHANNEL TREK1; UNCLASSIFIED DRUG; [(5,6,7,8 TETRAHYDRONAPHTHALEN 1 YL) 2 (1H TETRAZOL 5 YL)AMINE];

ARTICLE; CHANNEL GATING; DENSITY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; PATCH CLAMP TECHNIQUE; POINT MUTATION; PRIORITY JOURNAL;

FENAMATES; HEK293 CELLS; HUMANS; ION CHANNEL GATING; MUTATION; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; PROTEIN STRUCTURE, SECONDARY;

EID: 84897439035     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.091199     Document Type: Article

References (54)

1. Aller MI and Wisden W (2008) Changes in expression of some two-pore domain potassium channel genes (KCNK) in selected brain regions of developing mice. Neuroscience 151:1154-1172.
2. Alloui A, Zimmermann K, Mamet J, Duprat F, Noël J, Chemin J, Guy N, Blondeau N, Voilley N, and Rubat-Coudert C et al. (2006) TREK-1, a K+ channel involved in polymodal pain perception. EMBO J 25:2368-2376.
3. Bagriantsev SN, Clark KA, and Minor DL, Jr (2012) Metabolic and thermal stimuli control K(2P)2.1 (TREK-1) through modular sensory and gating domains. EMBO J 31:3297-3308.
4. Bagriantsev SN, Peyronnet R, Clark KA, Honoré E, and Minor DL, Jr (2011) Multiple modalities converge on a common gate to control K2P channel function. EMBO J 30:3594-3606.
5. Bittner S, Ruck T, Schuhmann MK, Herrmann AM, Moha ou Maati H, Bobak N, Göbel K, Langhauser F, Stegner D, and Ehling P et al. (2013) Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS. Nat Med 19:1161-1165.
6. Brohawn SG, Campbell EB, and MacKinnon R (2013) Domain-swapped chain connectivity and gated membrane access in a Fab-mediated crystal of the human TRAAK K+ channel. Proc Natl Acad Sci USA 110:2129-2134.
7. Cain SM, Meadows HJ, Dunlop J, and Bushell TJ (2008) mGlu4 potentiation of K(2P) 2.1 is dependant on C-terminal dephosphorylation. Mol Cell Neurosci 37:32-39.
8. Cao L, Veale EL, Mathie A, and Stevens E (2010). Differential modulation of TREK-1, TASK-3 and TRESK K2P ion channels by BL-1249 (Abstract), in 2010 Neuroscience Meeting Planner; 2010 Nov 13-17; San Diego, CA. Program No. 174.6/KK13, Society for Neuroscience, Washington, DC.
9. Cohen A, Ben-Abu Y, and Zilberberg N (2009) Gating the pore of potassium leak channels. Eur Biophys J 39:61-73.
10. Duprat F, Lesage F, Patel AJ, Fink M, Romey G, and Lazdunski M (2000) The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK. Mol Pharmacol 57:906-912.
11. Eckert M, Egenberger B, Döring F, and Wischmeyer E (2011) TREK-1 isoforms generated by alternative translation initiation display different susceptibility to the antidepressant fluoxetine. Neuropharmacology 61:918-923.
12. Enyedi P and Czirják G (2010) Molecular background of leak K+ currents: two-pore domain potassium channels. Physiol Rev 90:559-605.
13. Farrugia G, Rae JL, and Szurszewski JH (1993) Characterization of an outward potassium current in canine jejunal circular smooth muscle and its activation by fenamates. J Physiol 468:297-310.
14. Fernandez D, Sargent J, Sachse FB, and Sanguinetti MC (2008) Structural basis for ether-a-go-go-related gene K+ channel subtype-dependent activation by niflumic acid. Mol Pharmacol 73:1159-1167.
15. Fink M, Duprat F, Lesage F, Reyes R, Romey G, Heurteaux C, and Lazdunski M (1996) Cloning, functional expression and brain localization of a novel unconventional outward rectifier K+ channel. EMBO J 15:6854-6862.
16. Garg P and Sanguinetti MC (2012) Structure-activity relationship of fenamates as Slo2.1 channel activators. Mol Pharmacol 82:795-802.
17. Garg V, Stary-Weinzinger A, Sachse F, and Sanguinetti MC (2011) Molecular determinants for activation of human ether-à-go-go-related gene 1 potassium channels by 3-nitro-n-(4-phenoxyphenyl) benzamide. Mol Pharmacol 80:630-637.
18. Gruss M, Bushell TJ, Bright DP, Lieb WR, Mathie A, and Franks NP (2004) Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol 65:443-452.
19. Heurteaux C, Guy N, Laigle C, Blondeau N, Duprat F, Mazzuca M, Lang-Lazdunski L, Widmann C, Zanzouri M, and Romey G et al. (2004) TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J 23:2684-2695.
20. Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thümmler S, Peng XD, Noble F, Blondeau N, Widmann C, and Borsotto M et al. (2006) Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci 9:1134-1141.
21. Higgins DG, Thompson JD, and Gibson TJ (1996) Using CLUSTAL for multiple sequence alignments. Methods Enzymol 266:383-402.
22. Honoré E (2007) The neuronal background K2P channels: focus on TREK1. Nat Rev Neurosci 8:251-261.
23. Honoré E, Maingret F, Lazdunski M, and Patel AJ (2002) An intracellular proton sensor commands lipid-and mechano-gating of the K(+) channel TREK-1. EMBO J 21:2968-2976.
24. Hosaka Y, Iwata M, Kamiya N, Yamada M, Kinoshita K, Fukunishi Y, Tsujimae K, Hibino H, Aizawa Y, and Inanobe A et al. (2007) Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant. Channels (Austin) 1:198-208.
25. Kennard LE, Chumbley JR, Ranatunga KM, Armstrong SJ, Veale EL, and Mathie A (2005) Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br J Pharmacol 144:821-829.
26. Ma XY, Yu JM, Zhang SZ, Liu XY, Wu BH, Wei XL, Yan JQ, Sun HL, Yan HT, and Zheng JQ (2011) External Ba2+ block of the two-pore domain potassium channel TREK-1 defines conformational transition in its selectivity filter. J Biol Chem 286:39813-39822.
27. Maingret F, Lauritzen I, Patel AJ, Heurteaux C, Reyes R, Lesage F, Lazdunski M, and Honoré E (2000a) TREK-1 is a heat-activated background K(+) channel. EMBO J 19:2483-2491.
28. Maingret F, Patel AJ, Lesage F, Lazdunski M, and Honoré E (2000b) Lysophospholipids open the two-pore domain mechano-gated K(+) channels TREK-1 and TRAAK. J Biol Chem 275:10128-10133.
29. Marsh B, Acosta C, Djouhri L, and Lawson SN (2012) Leak K+ channel mRNAs in dorsal root ganglia: relation to inflammation and spontaneous pain behaviour. Mol Cell Neurosci 49:375-386.
30. Mathie A (2010) Ion channels as novel therapeutic targets in the treatment of pain. J Pharm Pharmacol 62:1089-1095.
31. Mathie A, Al-Moubarak E, and Veale EL (2010) Gating of two pore domain potassium channels. J Physiol 588:3149-3156.
32. Noël J, Sandoz G, and Lesage F (2011) Molecular regulations governing TREK and TRAAK channel functions. Channels (Austin) 5:402-409.
33. Noël J, Zimmermann K, Busserolles J, Deval E, Alloui A, Diochot S, Guy N, Borsotto M, Reeh P, and Eschalier A et al. (2009) The mechano-activated K+ channels TRAAK and TREK-1 control both warm and cold perception. EMBO J 28: 1308-1318.
34. Ozaita A and Vega-Saenz de Miera E (2002) Cloning of two transcripts, HKT4.1a and HKT4.1b, from the human two-pore K+ channel gene KCNK4. Chromosomal localization, tissue distribution and functional expression. Brain Res Mol Brain Res 102:18-27.
35. Patel AJ, Honoré E, Maingret F, Lesage F, Fink M, Duprat F, and Lazdunski M (1998) A mammalian two pore domain mechanogated S-like K+ channel. EMBO J 17:4283-4290.
36. Patel AJ, Honoré E, Lesage F, Fink M, Romey G, and Lazdunski M (1999) Inhalational anesthetics activate two-pore-domain background K+ channels. Nat Neurosci 2:422-426.
37. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, and Attali B (2005) Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol 67:1053-1066.
38. Peretz A, Degani-Katzav N, Talmon M, Danieli E, Gopin A, Malka E, Nachman R, Raz A, Shabat D, and Attali B (2007) A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives. PLoS ONE 2:e1332.
39. Perry M, Sanguinetti M, and Mitcheson J (2010) Revealing the structural basis of action of hERG potassium channel activators and blockers. J Physiol 588:3157-3167.
40. Piechotta PL, Rapedius M, Stansfeld PJ, Bollepalli MK, Ehrlich G, Andres-Enguix I, Fritzenschaft H, Decher N, Sansom MS, and Tucker SJ et al. (2011) The pore structure and gating mechanism of K2P channels. EMBO J 30:3607-3619.
41. Rapedius M, Schmidt MR, Sharma C, Stansfeld PJ, Sansom MS, Baukrowitz T, and Tucker SJ (2012) State-independent intracellular access of quaternary ammonium blockers to the pore of TREK-1. Channels (Austin) 6:473-478.
42. Rinné S, Renigunta V, Schlichthörl G, Zuzarte M, Bittner S, Meuth SG, Decher N, Daut J, and Preisig-Müller R (2013) A splice variant of the two-pore domain potassium channel TREK-1 with only one pore domain reduces the surface expression of full-length TREK-1 channels. Pflugers Arch DOI: 10.1007/s00424-013-1384-z [published ahead of print].
43. Sali A and Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815.
44. Sandoz G, Thümmler S, Duprat F, Feliciangeli S, Vinh J, Escoubas P, Guy N, Lazdunski M, and Lesage F (2006) AKAP150, a switch to convert mechano-, pHand arachidonic acid-sensitive TREK K(+) channels into open leak channels. EMBO J 25:5864-5872.
45. Sandoz G, Levitz J, Kramer RH, and Isacoff EY (2012) Optical control of endogenous proteins with a photos witchable conditional subunit reveals a role for TREK1 in GABAB signaling. Neuron 74:1005-1014.
46. Simkin D, Cavanaugh EJ, and Kim D (2008) Control of the single channel conductance of K2P10.1 (TREK-2) by the amino-terminus: role of alternative translation initiation. J Physiol 586:5651-5663.
47. Staudacher K, Baldea I, Kisselbach J, Staudacher I, Rahm AK, Schweizer PA, Becker R, Katus HA, and Thomas D (2011) Alternative splicing determines mRNA translation initiation and function of human K(2P)10.1 K+ channels. J Physiol 589: 3709-3720.
48. Takahira M, Sakurai M, Sakurada N, and Sugiyama K (2005) Fenamates and diltiazem modulate lipid-sensitive mechano-gated 2P domain K(+) channels. Pflugers Arch 451:474-478.
49. Talley EM, Solorzano G, Lei Q, Kim D, and Bayliss DA (2001) Cns distribution of members of the two-pore-domain (KCNK) potassium channel family. J Neurosci 21:7491-7505.
50. Tertyshnikova S, Knox RJ, Plym MJ, Thalody G, Griffin C, Neelands T, Harden DG, Signor L, Weaver D, and Myers RA et al. (2005) BL-1249 [(5,6,7,8-tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine]: a putative potassium channel opener with bladder-relaxant properties. J Pharmacol Exp Ther 313:250-259.
51. Thomas D, Plant LD, Wilkens CM, McCrossan ZA, and Goldstein SA (2008) Alternative translation initiation in rat brain yields K2P2.1 potassium channels permeable to sodium. Neuron 58:859-870.
52. Veale EL, Hassan M, Walsh Y, Al-Moubarak E, and Mathie A (2014) Recovery of current through mutated TASK3 potassium channels underlying Birk Barel syndrome. Mol Pharmacol 85:397-407.
53. Veale EL, Rees KA, Mathie A, and Trapp S (2010) Dominant negative effects of a non conducting TREK1 splice variant expressed in brain. J Biol Chem 285: 29295-29304.
54. Woolf CJ and Ma Q (2007) Nociceptors-noxious stimulus detectors. Neuron 55: 353-364.